Download the Case Study
Phase II, Type 2 Diabetes Trial
Phase II, Type 2 Diabetes Trial
Strategies to Accelerate Enrollment Timelines for Trials in Commonly Spread Diseases
The enrollment and retention of study participants is critical in ensuring a trial runs smoothly and without delay. But for many studies, especially those for common or widely spread diseases with many competing trials, recruitment and retention can present a significant challenge and pose a risk to delaying timelines, adding cost, and impacting probability of success.
The following case study outlines strategies that Medpace has taken to accelerate the enrollment timeline, contributing to the successful execution of a recent Phase II, Type 2 Diabetes study.
Your Diabetic Breakthrough Starts Here
Endorcrine & Metabolic CRO
With a successful track record of approvable NDA submissions, deep therapeutic expertise and decades of experience, Medpace can successfully navigate the operational complexities and regulatory scrutiny that endocrine and metabolic development programs often face. We have experience in recruiting historically difficult and highly competitive patient populations (both adult and pediatric), including patients with type 1 and type 2 diabetes.
At Medpace, we understand that patient engagement in diabetes trials can be challenging, with factors such as long study durations, glucose monitoring requirements, and complex drug regimens contributing to patient drop-out. Our team has the knowledge and tools to implement retention strategies that help mitigate these risks, ensuring studies run smoothly and generate high-quality data.
